HROW vs. HALO
HROW (Harrow Health, Inc.) and HALO (Halozyme Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — HROW in Drug Manufacturers - Specialty & Generic, HALO in Biotechnology. Over the past 10 years, HROW returned 23.55%/yr vs 21.91%/yr for HALO. At a 0.12 correlation, their price movements are largely independent.
Performance
HROW vs. HALO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HROW achieves a -32.00% return, which is significantly lower than HALO's 3.74% return. Over the past 10 years, HROW has outperformed HALO with an annualized return of 23.55%, while HALO has yielded a comparatively lower 21.91% annualized return.
HROW
- 1D
- 1.40%
- 1M
- -17.11%
- YTD
- -32.00%
- 6M
- -25.16%
- 1Y
- 13.57%
- 3Y*
- 19.43%
- 5Y*
- 29.87%
- 10Y*
- 23.55%
HALO
- 1D
- 5.34%
- 1M
- 8.13%
- YTD
- 3.74%
- 6M
- 7.98%
- 1Y
- 30.97%
- 3Y*
- 27.65%
- 5Y*
- 12.08%
- 10Y*
- 21.91%
HROW vs. HALO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HROW Harrow Health, Inc. | -32.00% | 46.05% | 199.55% | -24.12% | 70.83% | 25.95% | -11.83% | 36.73% | 234.71% | -32.00% |
HALO Halozyme Therapeutics, Inc. | 3.74% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
Correlation
The correlation between HROW and HALO is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Oct 1, 2007 | 0.12 |
Fundamentals
HROW:
$1.24B
HALO:
$8.58B
HROW:
-$0.39
HALO:
$2.87
HROW:
4.70
HALO:
5.64
HROW:
43.76
HALO:
39.06
HROW:
$268.68M
HALO:
$1.51B
HROW:
$199.11M
HALO:
$1.23B
HROW:
$22.70M
HALO:
$980.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HROW vs. HALO — Risk / Return Rank
HROW
HALO
HROW vs. HALO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HROW | HALO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.83 | ||
| Sortino ratioReturn per unit of downside risk | -0.82 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.19 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 0.29 | 1.29 | -1.00 |
| Martin ratioReturn relative to average drawdown | 0.66 | 2.47 | -1.81 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| HROW | HALO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.21 | 1.04 | -0.83 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.43 | 0.31 | +0.12 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.33 | 0.51 | -0.18 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.05 | 0.23 | -0.28 |
Drawdowns
HROW vs. HALO - Drawdown Comparison
The maximum HROW drawdown since its inception was -99.46%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HROW and HALO.
Loading charts...
Drawdown Indicators
| HROW | HALO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.46% | -74.26% | -25.20% |
Max Drawdown (1Y)Largest decline over 1 year | -47.03% | -24.13% | -22.90% |
Max Drawdown (3Y)Largest decline over 3 years | -63.32% | -33.92% | -29.40% |
Max Drawdown (5Y)Largest decline over 5 years | -71.15% | -49.06% | -22.09% |
Max Drawdown (10Y)Largest decline over 10 years | -71.15% | -49.06% | -22.09% |
Current DrawdownCurrent decline from peak | -75.86% | -14.05% | -61.81% |
Average DrawdownAverage peak-to-trough decline | -86.74% | -31.91% | -54.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.50% | 12.55% | +7.95% |
Volatility
HROW vs. HALO - Volatility Comparison
Harrow Health, Inc. (HROW) has a higher volatility of 29.71% compared to Halozyme Therapeutics, Inc. (HALO) at 11.55%. This indicates that HROW's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HROW | HALO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.71% | 11.55% | +18.16% |
Volatility (6M)Calculated over the trailing 6-month period | 55.43% | 24.29% | +31.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 64.81% | 30.34% | +34.47% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 69.96% | 39.53% | +30.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.13% | 42.91% | +28.22% |
Dividends
HROW vs. HALO - Dividend Comparison
Neither HROW nor HALO has paid dividends to shareholders.
Financials
HROW vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Harrow Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HROW vs. HALO - Profitability Comparison
HROW - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harrow Health, Inc. reported a gross profit of 27.05M and revenue of 44.20M. Therefore, the gross margin over that period was 61.2%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
HROW - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harrow Health, Inc. reported an operating income of -22.08M and revenue of 44.20M, resulting in an operating margin of -50.0%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
HROW - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harrow Health, Inc. reported a net income of -27.60M and revenue of 44.20M, resulting in a net margin of -62.4%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
Frequently Asked Questions
HROW and HALO have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HROW has higher volatility (29.71%) compared to HALO (11.55%). In terms of maximum drawdown, HROW dropped -99.46% vs HALO's -74.26%.
HALO currently has the higher Sharpe Ratio (1.04 vs 0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HROW and HALO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer